# EDGAR Filing Document

**Accession Number:** 0001124105
**File Stem:** 0001140361-26-025324
**Filing Date:** 2026-6
**Character Count:** 6636
**Document Hash:** 2f3782aa3a50d782048833c392ae3541
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-26-025324.hdr.sgml**: 20260616

**ACCESSION NUMBER**: 0001140361-26-025324

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260610

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260616

**DATE AS OF CHANGE**: 20260616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GYRE THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001124105
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 562020050
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-51173
- **FILM NUMBER:** 261092841

**BUSINESS ADDRESS:**
- **STREET 1:** 12730 HIGH BLUFF DRIVE
- **STREET 2:** SUITE 250
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130
- **BUSINESS PHONE:** (858) 284-0115

**MAIL ADDRESS:**
- **STREET 1:** 12730 HIGH BLUFF DRIVE
- **STREET 2:** SUITE 250
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92130

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CATALYST BIOSCIENCES, INC.
- **DATE OF NAME CHANGE:** 20150820

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TARGACEPT INC
- **DATE OF NAME CHANGE:** 20000919

?xml version='1.0' encoding='ASCII'?

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### WASHINGTON, D.C. 20549

------

#### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): **June 10, 2026**

## Gyre Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware 000-51173 56-2020050 <br> (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)

---

| | |
|:---|:---|
| **12730 High Bluff Drive**<br>**Suite 250**<br>**San Diego, CA**<br>| 92130<br>|
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(858) 284-0115**

#### N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which<br> registered<br>|
| Common Stock<br>| GYRE<br>| The Nasdaq Capital Market<br>|

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 5.07.** | **Submission of Matters to a Vote of Security Holders.** |

---

On June 10, 2026, Gyre Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). As of the close of business on April 16, 2026, the record date for the Annual Meeting, there were 96,994,001 shares of common stock entitled to vote at the meeting.

At the Annual Meeting, each of the Company's director nominees was elected and the other proposals voted on were approved. The proposals are described in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 27, 2026. The final voting results are set forth below.

#### Proposal 1: Election of Directors
The following Class II director nominees were elected to serve until the 2029 Annual Meeting of Stockholders based upon the following votes:

---

| | | | |
|:---|:---|:---|:---|
| **Nominee** | **Votes**<br> **For** | **Votes**<br> **Withheld** | **Broker**<br> **Non-Votes** |
| •&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; David M. Epstein, Ph.D. | 70,160,332 | 354,109 | 1,985,197 |
| •&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dan Weng, M.D. | 70,483,425 | 31,016 | 1,985,197 |

---

#### Proposal 2: Non-Binding Advisory Vote on Executive Compensation
The compensation of the Company's named executive officers was approved, on a non-binding, advisory basis, as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes**<br> **For** | **Votes**<br> **Against** | **Abstentions** | **Broker**<br> **Non-Votes** |
| 70,478,374 | 34,907 | 1,160 | 1,985,197 |

---

#### Proposal 3: Ratification of Independent Auditor
The appointment of Grant Thornton Zhitong Certified Public Accountants LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 was ratified as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes**<br> **For** | **Votes**<br> **Against** | **Abstentions** | **Broker**<br> **Non-Votes** |
| 72,487,596 | 11,626 | 416 | 0 |

---

#### Proposal 4: Approval of Conversion of Series B Preferred Stock
The issuance of shares of the Company's common stock, par value $0.001 per share, upon conversion of the Company's Series B Convertible Preferred Stock, par value $0.001 per share, was approved, in accordance with Nasdaq Listing Rule 5635(a), as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes**<br> **For** | **Votes**<br> **Against** | **Abstentions** | **Broker**<br> **Non-Votes** |
| 70,497,125 | 16,031 | 1,285 | 1,985,197 |

---

------

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | GYRE THERAPEUTICS, INC. | GYRE THERAPEUTICS, INC. |
| Date: June 16, 2026 | By: | /s/ Thomas Eastling |
|  | Name: | Thomas Eastling |
|  | Title: | Chief Financial Officer |

---

------